Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria

BMC Clinical Pharmacology

Kesiena J Akpoigbe¹  Titilope Badru²  George I Eluwa² 

[1]Society for Family Health, Abuja, Nigeria

[2]Department of Health Policy and Management, Diadem Consults Ltd, Abuja, Nigeria

关键词: Risk factors;    Incidence;    Nigeria;    HIV/AIDS;    Tenofovir;    Stavudine;    Zidovudine;    Antiretroviral;    ADR;    Adverse drug reactions;   

Others  :  860788
DOI  :  10.1186/1472-6904-12-7

 received in 2011-09-14, accepted in 2012-02-27,  发布年份 2012

【 摘 要 】

Background

Data on adverse drug reactions (ADRs) related to antiretroviral (ARV) use in public health practice are few indicating the need for ART safety surveillance in clinical care.

Objectives

To evaluate the incidence, type and risk factors associated with adverse drug reactions (ADRs) among patients on antiretroviral drugs (ARV).

Methods

Patients initiated on ARVs between May 2006 and May 2009 were evaluated in a retrospective cohort analysis in three health facilities in Nigeria. Regimens prescribed include nucleoside backbone of zidovudine (AZT)/lamivudine (3TC), stavudine (d4T)/3TC, or tenofovir (TDF)/3TC in combination with either nevirapine (NVP) or efavirenz (EFV). Generalized Estimating Equation (GEE) model was used to identify risk factors associated with occurrence of ADR.

Results

2650 patients were followed-up for 2456 person-years and reported 114 ADRs (incidence rate = 4.6/100 person-years).There were more females 1706(64%) and 73(64%) of the ADRs were reported by women. Overall, 61(54%) of ADRs were reported by patients on AZT with 54(47%) of these occurring in patients on AZT/NVP. The commonest ADRs reported were pain 25(30%) and skinrash 10(18%). Most ADRs were grade 1(39%) with only 1% being life threatening (grade 4). Adjusted GEE analysis showed that ADR was less likely to occur in patients on longer duration of ART compared to the first six months on treatment; 6-12 months AOR 0.38(95% CI:0.16-0.91) and 12-24 months AOR 0.34(95% CI:0.16-0.73) respectively. Compared to patients on TDF, ADR was less likely to occur in patients on d4T and AZT AOR 0.18(95% CI 0.05-0.64) and AOR 0.24(95% CI:0.7-0.9) respectively. Age, gender and CD4 count were not significantly associated with ADRs.

Conclusion

ADRs are more likely to occur within the first six months on treatment. Close monitoring within this period is required to prevent occurrence of severe ADR and improve ART adherence. Further research on the tolerability of tenofovir in this environment is recommended.

【 授权许可】

   
2012 Eluwa et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. AIDS Cohort Study Investigators JAMA 1998, 280:1497-1503.
• [2]Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS: Improved survival among HIV infected patients after initiation of triple drug antiretroviral regimens. CMAJ 1999, 160(Suppl 5):659-665.
• [3]Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human imunodeficiency virus infection. HIV outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
• [4]Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F, Antiprotease Cohort (APROCO) Study Group: Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV infected adults initiating protease inhibitor containing therapy. Infectious Dis Soc Am 2004, 39:248-255.
• [5]Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N: Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infectious Dis 2007, 45:1093-1101.
• [6]Patrice S, Juste MA, Ambroise A, Eliacin L, et al.: Early versus standard antiretroviral therapy for HIV infected adults in Haiti. N Engl J Med 2010, 363:257-265.
• [7]Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, et al.: Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. JAIDS 2000, 23:236-245.
• [8]Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL: Treatment of tuberculosis in HIV infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75-83.
• [9]World Health Organization: Pharmacovigilance for antiretrovirals in resource poor countries. medicines policy and standards. Geneva, World Health Organization 2007.
• [10]Laurent C, Bourgeois A, Mpoudi-Ngolé E, Ciaffi L, Kouanfack C, Mougnutou R, Nkoué N, Calmy A, Koulla-Shiro S, Delaporte E: Tolerability and effectiveness of first line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Human Retroviruses 2008, 24(Suppl 3):393-399.
• [11]Pollard RB, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20:1071-1092.
• [12](DHHS), U. S. D. o. H. a. H. S: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on antiretroviral guidelines for adults and adolescents 2006.
• [13]Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, Geretti AM, Johnson M, Leen C, Peters B, Pozniak A, Ross J, Walsh J, Wilkins E, Youle M: British HIV association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy. HIV Med 2006, 7(Suppl 8):487-503.
• [14]Colebunders R, Kamya MR, Laurence J, Kambugu A, Byakwaga H, Songa Mwebaze P, Muganzi Muganga A, Katwere M, Katabira E, Muganzi A: First-line antiretroviral therapy in Africa, how evidence based are our recommendations? AIDS Rev 2005, 7(Suppl 3):148-154.
• [15]Montessori V, Press N, Harris M, Akagi L, Montaner JSG: Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc Licensors 2004, 170(Suppl 2):229-238.
• [16]Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, Djedje M, Farquhar C: Antiretroviral associated toxicity among HIV 1 seropositive pregnant women in Mozambique receiving nevirapine based regimens. J Acquir Immune Defic Syndr 2007, 44(Suppl 4):371-376.
• [17]Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, Limpongsanurak S, Jadwattanakul T, Eiamapichart P, Luesomboon W, Apisarnthanarak A, Kamudhamas A, Tangsathapornpong A, Vitavasiri C, Singhakowinta N, Attakornwattana V, Kriengsinyot R, Methajittiphun P, Chunloy K, Preetiyathorn W, Aumchantr T, Toro P, Abrams EJ, El-Sadr W, Phanuphak P: Nevirapine associated toxicity in HIV-infected Thai men and women, including pregnant women. Br HIV Assoc 2007, 8:357-366.
• [18]Dieterich DT, Love J, Stern JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38(Suppl 2):S80-S89.
• [19]Baylor MS, Johann-Liang R: Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004, 35:538.
• [20]Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr 2003, 34:S21-S33.
• [21]de Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH: Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine containing antiretroviral treatment. AIDS 2003, 17:2209-2214.
• [22]Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM: Hepatotoxicity in HIV infected patients recieving nevirapine containing antiretroviral therapy. AIDS 2001, 15:1261-1268.
• [23]Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD: Hepatotoxicity associated with nevirapine or efavirenz containing antiretroviral therapy:role of hepatitis C and B infections. Hepatology 2003, 1:35.
• [24]Asuzu MC: The necessity for a health systems reform in Nigeria. J Community Med & Primary Health Care 2000, 16:1-3.
• [25]Federal Ministry of Health Abuja, Nigeria: National guidelines for HIV/AIDS treatment and care in adolescents and adults. 2010.
• [26]World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. [http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf] webciteWHO 2006, 28. (accessed December 3rd, 2011)
• [27]World Health Organization: Assuring safety of preventive chemotherapy interventions for neglected tropical diseases. practical advice for national programme managers on the prevention, detection and management of serious adverse effects. [http://whqlibdoc.who.int/publications/2011/9789241502191_eng.pdf] webciteWHO 2011, 1. (accessed December 3rd, 2011)
• [28]Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrica 1986, 73:13-22.
• [29]Liang KY, Zeger SL: Regression analysis for correlated data. Annu Rev Publ Health 1993, 14:43-68.
• [30]Reid A, Walker S, Ssali F, Munderi P, Gilks C: Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa [abstract THAB0105]. International AIDS Society 2006.
• [31]Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ: Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007, 44(Suppl 4):456-462.
• [32]Kumarasamy N, Lai A, Cecelia AJ, et al.: Toxicities and adverse events following generic HAART in south Indian HIV-infected individuals [abstract P189]. Proceedings of the 7th International Congress on Drug Therapy and HIV Infection (Glasgow, United Kingdom) 2004.
• [33]Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO: A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med 2002, 21:83-86.
• [34]Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X: Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Coˆ te d'Ivoire. Antivir Ther 2005, 10:615-624.
• [35]Shah I: Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006, 52:244-248.
• [36]Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD Jr, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353:2325-2334.
• [37]Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Triviño L, Makakole L, Ford N: Renal safety of tenofovir containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One 2011, 6(Suppl 3):e17609.
• [38]Lucas GM, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131(Suppl 2):81-87.
• [39]Forster M, Bailey Christopher, Brinkhof MartinWG: Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programs in resource-limited settings. Bull World Health Organization 2008, 86:939-947.